Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
More than 120 speakers and 5,000 delegates are expected to attend
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
_256_384.jpg)
Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The first-of-its-kind unique centre will increase access to preventive & primary care
Subscribe To Our Newsletter & Stay Updated
